Table 2.
Effects of Pi∗MZ genotype on hepatic decompensation and liver transplant or liver-related death.
| Model | Hepatic decompensation |
Liver transplant or liver-related death |
||
|---|---|---|---|---|
| Hazard ratio | p value | Hazard ratio | p value | |
| Model 1 | 1.81 (1.22-2.69) | 0.0032 | 2.07 (1.21-3.52) | 0.0078 |
| Model 2 | 1.80 (1.22-2.65) | 0.0030 | 1.86 (1.07-3.23) | 0.027 |
| Model 3 | 1.80 (1.22-2.65) | 0.003 | 1.92 (1.10-3.36) | 0.021 |
| Model 4 | 1.79 (1.19-2.67) | 0.0047 | 1.90 (1.10-3.28) | 0.022 |
| Model 5 | 1.80 (1.22-2.68) | 0.0033 | 1.80 (1.02-3.18) | 0.041 |
Hazard ratios (95% Cl) for Pi∗MZ relative to Pi∗MM. Model 1 is adjusted for age, sex, disease etiology (non-alcoholic fatty liver disease or cryptogenic vs. other etiologies), and principal components 1-10. Model 2 is adjusted for model 1 covariates plus albumin. Model 3 is adjusted for model 1 covariates plus platelet count. Model 4 is adjusted for model 1 covariates plus model for end-stage liver disease score. Model 5 is adjusted for model 1 covariates plus platelet count and model for end-stage liver disease score. p value was generated using a Fine-Gray competing risk model.